Scotia Capital Inc. Acquires 541 Shares of Axon Enterprise, Inc $AXON

Scotia Capital Inc. boosted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 40.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,869 shares of the biotechnology company’s stock after buying an additional 541 shares during the period. Scotia Capital Inc.’s holdings in Axon Enterprise were worth $1,547,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC bought a new stake in Axon Enterprise during the fourth quarter valued at about $480,000. Cheviot Value Management LLC purchased a new stake in shares of Axon Enterprise during the first quarter valued at about $86,000. IPG Investment Advisors LLC lifted its position in shares of Axon Enterprise by 28.1% during the first quarter. IPG Investment Advisors LLC now owns 2,230 shares of the biotechnology company’s stock valued at $1,173,000 after buying an additional 489 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after buying an additional 212,931 shares in the last quarter. Finally, iA Global Asset Management Inc. grew its position in shares of Axon Enterprise by 2.6% in the 1st quarter. iA Global Asset Management Inc. now owns 8,434 shares of the biotechnology company’s stock worth $4,436,000 after buying an additional 215 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 1.4%

NASDAQ:AXON opened at $532.38 on Tuesday. The company has a market capitalization of $42.01 billion, a P/E ratio of 131.45, a PEG ratio of 29.49 and a beta of 1.45. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The firm has a fifty day simple moving average of $653.57 and a 200-day simple moving average of $725.45.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.45 earnings per share. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In related news, Director Jeri Williams sold 100 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director owned 1,416 shares in the company, valued at $1,065,596.64. This represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the transaction, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. This trade represents a 0.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 38,622 shares of company stock valued at $26,439,364 over the last three months. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on AXON. Needham & Company LLC reissued a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Barclays lowered their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Piper Sandler dropped their target price on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, UBS Group reduced their target price on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $814.00.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.